产品
编 号：F622534
分子式：C26H27FN4O5S.1/2C4H4O4
分子量：584.62
分子式：C26H27FN4O5S.1/2C4H4O4
分子量：584.62
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 1621688-31-0
产品详情
生物活性：
Roginolisib (MSC2360844) hemifumarate is a potent, orally active and selective PI3Kδ inhibitor, with an IC50 of 145 nM. Roginolisib hemifumarate shows highly selective against a panel of 278 additional kinases.
体内研究：
Roginolisib hemifumarate (6.6-66 mg/kg; daily from week 2 to 10) ameliorates disease manifestations in a murine SLE model.Animal Model:NZB/W F1 female mice
Dosage:6.6, 22, or 66?mg/kg
Administration:Oral; starting at week 2 post ADV-IFNα delivery, once daily at 10?weeks
Result:Significantly reduced proteinuria incidence and severity in a dose-dependent manner.
体外研究：
Roginolisib hemifumarate (0-10 μM; 1 hours) completely abolished BCR-induced pAkt in Ramos B cells in a concentration-dependent manner with IC50 values of 280 nM. Roginolisib hemifumarate inhibits B cell proliferation in a concentration-dependent manner with an IC50 of 48 nM. Roginolisib hemifumarate blocks BCR- and TCR-mediated responses in lymphocytes and TLR-induced IFNα by pDC in human primary cells.
Roginolisib (MSC2360844) hemifumarate is a potent, orally active and selective PI3Kδ inhibitor, with an IC50 of 145 nM. Roginolisib hemifumarate shows highly selective against a panel of 278 additional kinases.
体内研究：
Roginolisib hemifumarate (6.6-66 mg/kg; daily from week 2 to 10) ameliorates disease manifestations in a murine SLE model.Animal Model:NZB/W F1 female mice
Dosage:6.6, 22, or 66?mg/kg
Administration:Oral; starting at week 2 post ADV-IFNα delivery, once daily at 10?weeks
Result:Significantly reduced proteinuria incidence and severity in a dose-dependent manner.
体外研究：
Roginolisib hemifumarate (0-10 μM; 1 hours) completely abolished BCR-induced pAkt in Ramos B cells in a concentration-dependent manner with IC50 values of 280 nM. Roginolisib hemifumarate inhibits B cell proliferation in a concentration-dependent manner with an IC50 of 48 nM. Roginolisib hemifumarate blocks BCR- and TCR-mediated responses in lymphocytes and TLR-induced IFNα by pDC in human primary cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备